← Leaderboards
Michelle Ginsberg
Sloan-Kettering Inst Can Research
$961,910
Attributed
$2,885,730
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $734.5K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,885,730 · 1
By mechanism
R01$2,885,730 · 1
Top collaborators
- Michael F. Berger4 shared
- Alexander Drilon4 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- David B. Solit$21,393,031
- Sarat Chandarlapaty$10,852,142
- Raajit Rampal$5,822,249
- Ronglai Shen$3,190,387
- Elisa De Stanchina$4,011,743
Others in their field
Other Rising Stars on “Future”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Mari Ostendorf · University Of Washington$51,931,230
- Jeffrey Leintz · National Opinion Research Center$40,628,545
- Eric M Benway · Woods Hole Oceanographic Institution$32,293,242
- Walt Lee$25,884,232
- Cyrus Wadia · Activate Global, Inc.$24,000,000
Research focus
FutureGene FrequencyFrequenciesBiological MarkersCancer TherapyCancer TypeAreaCell Free DnaClinical TrialsCo-Clinical TrialCollectionComplementCone-Beam Computed TomographyCytotoxicDeep SequencingCategoriesDna SequencingDrug DevelopmentEarly Phase Clinical TrialEnrollmentFailureFallsFoundationsGenetic Variant
Grant awards (4)
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy$734,511
R01 · FY2025 · CA
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy$697,771
R01 · FY2024 · CA
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy$719,326
R01 · FY2023 · CA
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy$734,122
R01 · FY2022 · CA